Dr Jatinder Kapur – VP of Quality

Jatinder is Oxular’s Vice President of Quality. He has more than 25 years of experience in the quality assurance function, amassing extensive knowledge in the development and auditing processes of pharmaceuticals, including sterile injectables, oral dosage forms, and liquid suspension preparations, as well as medical devices. Jatinder has worked with several quality pharmaceutical companies, such as Novartis, Shire, and BTG, and has significant experience working with combination medical device and pharmaceutical products. He has overseen product technology transfers, designed and commissioned a sterile API plant, and established numerous quality management systems. He holds a PhD in Synthetic Organic Chemistry from Punjab University, India.

Ronald Yamamoto Chief Scientific Officer

Ronald is co-founder, Chief Scientific Officer, and a Board Observer of Oxular. With more than 30 years of medical device and drug product development experience, Ronald has led multi-disciplinary technical teams, clinical trial development, and product registration in the US, the EU, China, and Brazil. His ophthalmic experience includes the development of novel microcatheters for …

Ronald Yamamoto Chief Scientific Officer Read More »

Ian Anderson – Chief Technical Officer

Ian is Oxular’s Chief Technical Officer. He has significant experience in all technical aspects of medical device development and high-volume medical product industrialization. Ian journeyed from aeronautical and broadcast engineering into medical technologies, where he has been involved in the design, development, and launch of products as varied as surgical robots, auto-injector combination solutions, and stoma …

Ian Anderson – Chief Technical Officer Read More »

Dr. Dmitrij Hristodorov Director

Dmitrij is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as a board …

Dr. Dmitrij Hristodorov Director Read More »

Dr. Sam Williams

Sam has over 30 years’ experience in the Life Sciences sector as a scientist, company CEO and investment manager. He is currently Managing Partner at IP Group plc., the FTSE 250 investor, where he oversees the group’s c.£500m Life Sciences portfolio. He is founding CEO and Chairman of Istesso Ltd, a Phase 2 drug-discovery company, …

Dr. Sam Williams Read More »

Dr. Friedrich Asmus Chief Medical Officer

Friedrich, a board-certified neurologist and pharmacist is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. For more than a decade he has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was previously a key strategic contributor for retinal anti‑VEGF …

Dr. Friedrich Asmus Chief Medical Officer Read More »

David Fellows – Interim Chief Executive Officer

David is the Interim Chief Executive Officer of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously Chief Executive Officer of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the …

David Fellows – Interim Chief Executive Officer Read More »

Mark Gaffney – Chief Executive Officer

Mark has 20+ years of leadership experience in biotech & life sciences. He is motivated to find durable and safe treatments for blindness, influenced by his father’s retinitis pigmentosa. A former U.S. Air Force intelligence officer, Mark’s analytical problem-solving approach is backed by degrees in mechanical engineering and law. His dedication to innovation aims to …

Mark Gaffney – Chief Executive Officer Read More »

Jim Jogerst – Chief Business Officer

Jim is the Chief Business Officer for Oxular. He is an accomplished and seasoned business development and strategy executive with over 20 years of creating value for pharma/biotech companies and their stakeholders. His prior work experience includes extensive experience as CBO at Rubius Therapeutics (a Flagship company focused on red blood cell therapies for oncology and auto-immune), Janssen, Alcon/Novartis and executive leadership roles at several boutique investment banks. Jim built and led the business development and M&A teams at Alcon for approximately 10 years where he was responsible for external growth strategies for its three global franchises in surgical, pharma, and consumer.

Tassos Konstantinou Director

Tassos is an investment manager at IP Group and specializes in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (formerly CRT) where he led the intellectual property sourcing, licensing, and spin-out creation of CRUK-funded technologies. He has experience in technology transfer …

Tassos Konstantinou Director Read More »

Scroll to Top